EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische Studie

Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study

Miao-Zhen Qiu iD, Hongming Pan, Ka On Lam, Jufeng Wang, Yi Zheng, Huiping Li, Xinhong Wu, Li Wang, Lequn Bao, Jing Cheng, Yanxia Shi, Yunong Gao und 7 weitere

Cancer · 2025

DOI: 10.1002/cncr.35919 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, 2025. Verfasst von Miao-Zhen Qiu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Piperidines, Indazoles, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Bispecific. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Zai Lab (Shanghai) Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This open‐label, single‐arm, phase 1b dose escalation and expansion study ( ClinicalTrials.gov identifier NCT04178460) explored the safety, tolerability, and antitumor activity of tebotelimab, a programmed cell death protein 1 × lymphocyte‐activation gene 3 bispecific monoclonal antibody, in combination with niraparib, a poly(adenosine diphosphate ribose) polymerase inhibitor, in patients with gastric cancer, triple‐negative breast cancer (TNBC), biliary tract carcinoma (BTC), and endometrial carcinoma.

Methods

In the escalation phase, patients with locally advanced or metastatic gastric cancer who failed ≥2 prior systemic treatments received tebotelimab (120, 300, or 600 mg) intravenously once every 2 weeks (Q2W). In the expansion phase, patients with previously treated gastric cancer, TNBC, BTC, or endometrial carcinoma received tebotelimab at the recommended phase 2 dose (RP2D). All patients received niraparib orally once daily with an individualized starting dose.

Results

From June 11, 2020, to January 29, 2022, 60 patients were enrolled. All received ≥1 dose of the study drug. The RP2D for tebotelimab was determined to be 600 mg Q2W, without dose‐limiting toxicities observed. Grade ≥3 and serious treatment‐emergent adverse events (TEAEs) occurred in 39 patients (65.0%) and 25 patients (41.7%), respectively, with no treatment‐related death. Immune‐related TEAEs occurred in 28 patients (46.7%). In those who had target lesions at baseline and received the RP2D, the investigator‐assessed, confirmed overall response rate per Response Evaluation Criteria in Solid Tumors, version 1.1, was 5.3% (one of 19), 20.0% (two of 10), 8.3% (one of 12), and 0% (zero of three) for gastric cancer, TNBC, BTC, and endometrial carcinoma, respectively.

Conclusions

Tebotelimab plus niraparib preliminarily demonstrated a tolerated and manageable safety profile and limited antitumor activity in patients with previously treated solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesIndazolesAntineoplastic Combined Chemotherapy ProtocolsAntibodies, BispecificNeoplasmsHumansFemaleMiddle AgedAgedAdultMalePoly(ADP-ribose) Polymerase InhibitorsAntibodies, Monoclonal, HumanizedAged, 80 and overMaximum Tolerated DoseNeoplasm MetastasisDose-Response Relationship, Drug

Stichwörter der Autor:innen

niraparibphase 1bsolid tumorstebotelimab

Substanzen

niraparibPiperidinesIndazolesAntibodies, BispecificPoly(ADP-ribose) Polymerase InhibitorsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Clinical Oncology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
  • Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou, China.
  • Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China.

ORCID-Profile: Miao-Zhen Qiu, Rui-Hua Xu

Förderung

  • Zai Lab (Shanghai) Co., Ltd

Zitieren

APA

Qiu, M. Z., Pan, H., Lam, K. O., Wang, J., Zheng, Y., Li, H., Wu, X., Wang, L., Bao, L., Cheng, J., Shi, Y., Gao, Y., Yan, M., Luo, H., Zheng, Y., Zhen, X., Hang, W., Hou, J., & Xu, R. H. (2025). Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study. Cancer. https://doi.org/10.1002/cncr.35919

Vancouver

Qiu MZ, Pan H, Lam KO, Wang J, Zheng Y, Li H, et al. Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study. Cancer. 2025. doi:10.1002/cncr.35919

BibTeX
@article{Qiu2025,
  author = {Qiu, Miao-Zhen and Pan, Hongming and Lam, Ka On and Wang, Jufeng and Zheng, Yi and Li, Huiping and Wu, Xinhong and Wang, Li and Bao, Lequn and Cheng, Jing and Shi, Yanxia and Gao, Yunong and Yan, Min and Luo, Huiyan and Zheng, Yu and Zhen, Xiaoa and Hang, Wenzhao and Hou, Jianmei and Xu, Rui-Hua},
  title = {Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35919}
}
Kostenlos starten →